Sanofi’s Sarclisa Gets EMA Backing In Myeloma, Mirroring FDA OK
But Experts Doubt It Can Overtake J&J’s Entrenched Darzalex
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.
